Fundamental studies of Cefixime(CFIX) in Mxillofacial surgery.

DOI
  • MOTOJI SHIGEKI
    Department of Mexillofacial Surgery, School of Medicine, Kobe University
  • TAKENONO IWAO
    Department of Mexillofacial Surgery, School of Medicine, Kobe University
  • OHTSUKA YOSHIKI
    Department of Mexillofacial Surgery, School of Medicine, Kobe University
  • NAKASUJI KANAKO
    Department of Mexillofacial Surgery, School of Medicine, Kobe University
  • HIRANO FUKI
    Department of Mexillofacial Surgery, School of Medicine, Kobe University
  • KOBAYASHI SOUICHIROU
    Department of Mexillofacial Surgery, School of Medicine, Kobe University
  • SANO EISAKU
    Department of Mexillofacial Surgery, School of Medicine, Kobe University
  • YOSHII TAKASHI
    Department of Mexillofacial Surgery, School of Medicine, Kobe University
  • NAKAO KAORU
    Department of Mexillofacial Surgery, School of Medicine, Kobe University
  • SHIMADA KEIKICHI
    Department of Mexillofacial Surgery, School of Medicine, Kobe University

Bibliographic Information

Other Title
  • Cefixime(CFIX)の口腔外科領域における基礎的検討

Search this article

Abstract

We carried out fundamental studies to evaluate the usefulness of Cefixime (CFIX) in maxillofacial surgery, and obtained the following results.<BR>1) The mean values of concentrations of CFIX after administration of 200mg P.O. to non-fasted patients were 2.42μg/ml (5 hr), 1.79μg/ml (7 hr) in serum, 0.95μg/ml (5 hr), and 0.65μg/ml (7 hr) in blood in wound. Gingival concentrations of CFIX were 0.21-1.17μg/g except 6 N.D.<BR>2) The antibacterial activity of CFIX against 65 Streptococcus sp. clinically isolated was equivalent to those of Ampicillin (ABPC), Cefteram (CFTM), Cefuroxime (CXM) Ofloxacin (OFLX) and superior to that of Cefaclor (CCL) at MIC80, but against 30 Staphyloccoccus sp. CFIX showed inferior antibacterial activity to other antibiotics. Among all antibiotics, CFIX showed the strongest antibactrial activity against arerobic gram-negative organisms.<BR>3) It was considered that CFIX was effective in the treatment of mild and moderate oral infections.

Journal

Details 詳細情報について

Report a problem

Back to top